Ginkgo Bioworks (NYSE: DNA) — Perfil da empresa, notícias e dados financeiros
Ginkgo Bioworks utilizes synthetic biology for cell programming, aiming to develop sustainable solutions in health and agriculture.
Ginkgo Bioworks
Ginkgo Bioworks (NYSE:DNA) specializes in cell programming, leveraging synthetic biology to design, develop, and manufacture organisms for a variety of applications including pharmaceuticals, agriculture, and biotechnology. Aimed at solving some of the world's most pressing challenges, its projects span across developing antibiotics, biofuels, and more sustainable food solutions. Ginkgo Bioworks operates with the objective to make biology as easy to engineer as computers, envisioning a future where its technology can bring about significant advancements in health, energy, and environmental sustainability.
Resumo
Operações
Produtos e/ou serviços de Ginkgo Bioworks
- Biosecurity and public health monitoring through the detection and analytics of pathogens, advancing global health safety.
- Synthetic biology and enzyme engineering for pharmaceutical and biotechnology applications, enhancing drug discovery and production.
- Agricultural biology solutions, improving crop resilience and yield through genetic innovation and microbial solutions.
- Sustainable bio-based chemicals production, reducing reliance on petroleum derivatives by creating eco-friendly alternatives.
- Bioremediation strategies, employing microorganisms to degrade environmental pollutants, aiding in ecological restoration.
- Nutrition and food technology advancements, engineering yeast and bacteria to produce alternative proteins and vitamins.
equipe executiva do Ginkgo Bioworks
- Jason KellyCo-Founder, Co-COO, CEO & Director
- Reshma P. ShettyCo-Founder, President & Director
- Steven P. CoenChief Financial Officer
- Thomas Knight Jr.Founder
- Austin CheCo-Founder & Head of Strategy
- Bartholomew CantonCo-Founder & CTO
- Jennifer WipfCo-Chief Operating Officer
- Karen TepichinGeneral Counsel & Secretary
- Daniel MarshallSenior Manager of Communications & Ownership
- Brian O'sullivanHead of Commercial
Principais indicadores financeiros
Resultados divulgados pela Ginkgo Bioworks, em USD.
- Cap. de mercado
- 758,9 mi
- Receita (TTM)
- 132,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -5.1
- Dividend yield
- —
- Margem de lucro
- -219.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 170,2 mi | -315,3 mi | -312,8 mi | |
| 227 mi | -559,8 mi | -547 mi | |
| 251,5 mi | -864,4 mi | -892,9 mi | |
| 477,7 mi | -2,2 bi | -2,1 bi |